Literature DB >> 26043697

Long non-coding RNA APTR promotes the activation of hepatic stellate cells and the progression of liver fibrosis.

Fujun Yu1, Jianjian Zheng2, Yuqing Mao1, Peihong Dong3, Guojun Li4, Zhongqiu Lu5, Chuanyong Guo6, Zhanju Liu6, Xiaoming Fan7.   

Abstract

In this study, we aimed at assessing a role of Alu-mediated p21 transcriptional regulator (APTR) in hepatofibrogenesis. APTR was upregulated in fibrotic liver samples and activated hepatic stellate cells (HSCs). Knockdown of APTR inhibited the activation of HSCs in vitro and mitigated the accumulation of collagen in vivo. Importantly, APTR silencing could abrogate TGF-β1-induced upregulation of α-SMA in HSCs. In addition, inhibition of cell cycle and cell proliferation by APTR knockdown was attenuated by p21 siRNA1 in primary HSCs. Finally, serum APTR levels were increased in patients with liver cirrhosis, indicating a potential biomarker for liver cirrhosis. Collectively, evidence is proposed for a new biological role of APTR in hepatofibrogenesis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alu-mediated p21 transcriptional regulator; Hepatic stellate cells; Liver fibrosis; Long non-coding RNA; p21

Mesh:

Substances:

Year:  2015        PMID: 26043697     DOI: 10.1016/j.bbrc.2015.05.124

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Down-Regulation of APTR and it's Diagnostic Value in Papillary and Anaplastic Thyroid Cancer.

Authors:  Ke Zhang; Cuilin Li; Jianqiu Liu; Zhi Li; Chao Ma
Journal:  Pathol Oncol Res       Date:  2018-12-11       Impact factor: 3.201

Review 2.  RWSF-BLP: a novel lncRNA-disease association prediction model using random walk-based multi-similarity fusion and bidirectional label propagation.

Authors:  Guobo Xie; Bin Huang; Yuping Sun; Changhai Wu; Yuqiong Han
Journal:  Mol Genet Genomics       Date:  2021-02-15       Impact factor: 3.291

3.  Methylation of the miR-126 gene associated with glioma progression.

Authors:  Hongwei Cui; Yongping Mu; Lei Yu; Ya-guang Xi; Rune Matthiesen; Xiulan Su; Wenjie Sun
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

4.  IRWNRLPI: Integrating Random Walk and Neighborhood Regularized Logistic Matrix Factorization for lncRNA-Protein Interaction Prediction.

Authors:  Qi Zhao; Yue Zhang; Huan Hu; Guofei Ren; Wen Zhang; Hongsheng Liu
Journal:  Front Genet       Date:  2018-07-04       Impact factor: 4.599

5.  LPI-NRLMF: lncRNA-protein interaction prediction by neighborhood regularized logistic matrix factorization.

Authors:  Hongsheng Liu; Guofei Ren; Huan Hu; Li Zhang; Haixin Ai; Wen Zhang; Qi Zhao
Journal:  Oncotarget       Date:  2017-10-19

6.  Knockdown of Long Noncoding RNA H19 Represses the Progress of Pulmonary Fibrosis through the Transforming Growth Factor β/Smad3 Pathway by Regulating MicroRNA 140.

Authors:  Xi Wang; Zhe Cheng; Lingling Dai; Tianci Jiang; Liuqun Jia; Xiaogang Jing; Lin An; Huan Wang; Meng Liu
Journal:  Mol Cell Biol       Date:  2019-05-28       Impact factor: 4.272

7.  HOTAIR Epigenetically Modulates PTEN Expression via MicroRNA-29b: A Novel Mechanism in Regulation of Liver Fibrosis.

Authors:  Fujun Yu; Bicheng Chen; Peihong Dong; Jianjian Zheng
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

8.  The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients.

Authors:  Akhmad Makhmudi; Reinaldo Supanji; Bayu Pratama Putra
Journal:  Pediatr Surg Int       Date:  2019-09-23       Impact factor: 1.827

9.  Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells.

Authors:  Fatjon Leti; Christophe Legendre; Christopher D Still; Xin Chu; Anthony Petrick; Glenn S Gerhard; Johanna K DiStefano
Journal:  Transl Res       Date:  2017-09-19       Impact factor: 7.012

Review 10.  Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets.

Authors:  B Alipoor; S Nikouei; F Rezaeinejad; S-N Malakooti-Dehkordi; Z Sabati; H Ghasemi
Journal:  J Endocrinol Invest       Date:  2021-04-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.